Entry Detail



General Information

Database ID:exR0090110
RNA Name:hsa-miR-520c-3p
RNA Type:miRNA
Chromosome:chr19
Starnd:+
Coordinate:
Start Site(bp):53707506End Site(bp):53707527
External Links:hsa-miR-520c-3p



Disease Information

Disease Name:Preterm Birth
Disease Category:Urogenital Diseases and Pregnancy Complications
MeSH ID:D047928
Type:Diseases Category/Female Urogenital Diseases and Pregnancy Complications
Alias:Premature Birth//Birth, Premature//Births, Premature//Premature Births//Preterm Birth//Birth, Preterm//Births, Preterm//Preterm Births



Expression Detail

GEO ID:GSE106224
Description:Exosomal RNA may reflect placenta deficiencies and provide better biomarker in preterm birth
Experimental Design:Disease vs Control
Case Disease Type:Preterm Birth
Case Disease SubType:NA
Case Sample:Preterm Birth
Control Sample:Control
Number of Case:20
Number of Control:50
Number of Samples:70





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
PDRG1
chr20
31944337
31952046
-
NAA16
chr13
41311267
41377030
+
IFNAR1
chr21
33324429
33359864
+
FYCO1
chr3
45917899
45995824
-
MSL1
chr17
40121971
40136917
+
ZFAND4
chr10
45615500
45672780
-
CLCN6
chr1
11806096
11848079
+
SYAP1
chrX
16719612
16765340
+
AMPD2
chr1
109616104
109632053
+
EIF5A2
chr3
170888418
170908644
-
PTP4A1
chr6
63521746
63583436
+
TNS1
chr2
217799588
218033982
-
CAMK2N1
chr1
20482391
20486210
-
RPP14
chr3
58306247
58324695
+
PHC3
chr3
170086732
170181749
-
HTD2
chr3
58306262
58318574
+
MBP
chr18
76978827
77133683
-
SLC7A2
chr8
17497088
17570573
+
TRIB1
chr8
125430358
125438403
+
SIRPA
chr20
1894167
1940592
+
CCSAP
chr1
229321011
229343294
-
SRRT
chr7
100875103
100888664
+
CHD9
chr16
53055033
53329150
+
FAM177A1
chr14
35044907
35113130
+
PLAGL2
chr20
32192504
32207743
-
CLIP4
chr2
29097705
29189643
+
NPAS2
chr2
100820139
100996829
+
LONP2
chr16
48244300
48363122
+
KLHL28
chr14
44924319
45042322
-
APP
chr21
25880550
26171128
-
miRNA targets:NA
circRNA targets:
circRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
hsa_circ_0000943
chr19
47421744
47440665
+
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AL049840.4
chr14
103694516
103695050
-
ARHGAP27P1-BPTFP1-KPNA2P3
chr17
64749663
64781707
-
FGD5-AS1
chr3
14920347
14948424
-
MIR17HG
chr13
91347820
91354579
+
NEAT1
chr11
65422774
65445540
+
NORAD
chr20
36045618
36051018
-
SNHG16
chr17
76557764
76565348
+
XIST
chrX
73820649
73852723
-
Display:



Experiment Detail

GEO ID:GSE106224
Sample Source:Blood
Source Fraction:Plasma
Platform:GPL18573
Method:NGS
Num of detected RNA Type:1
Num of detected RNAs of this Type:1522
Sample treatment protocol:Whole blood samples were centrifuged for 15 minutes at 2,000×g at 4°C to get plasma. EVs were isolated from 100 ul of plasma using size exclusion columns (iZON qEV, Cambridge MA) with de-gassed 1X PBS from a total of 22 selected samples, 11 from each group (Table 1). Eluate (~500 ul for each fraction) was collected in microfuge tubes individually. The protein contains and concentration for each fraction were assessed by protein gel electrophoresis and Bradford assay (BioRad, Hercules, CA).
RNA Extract protocol:RNA was isolated from all plasma samples, the 22 EV samples, and 22 corresponding EV-depleted fractions using miRNeasy Micro Kit (Qiagne, Germantown MD).
RNA library preparation protocol:Small RNA sequencing libraries were generated with a modified small RNAseq protocol (manuscript in preparation) that alleviates most of the adapter-miRNA ligation sequence bias problem.



Reference

PMID:29516617
Title:Extracellular vesicle RNAs reflect placenta dysfunction and are a biomarker source for preterm labour
Author:Fallen S, Baxter D, Wu X, Kim TK, Shynlova O, Lee MY, Scherler K, Lye S, Hood L, Wang K
Journal:J Cell Mol Med. 2018 May;22(5):2760-2773.
Description:We have used an improved small RNA library construction protocol and a newly developed size exclusion chromatography (SEC)-based EV purification method to gain a comprehensive view of circulating RNA in plasma and its distribution by analysing RNAs in whole plasma and EV-associated and EV-depleted plasma.